

TB EUROPE COALITION ANNUAL ACCOUNTS 2024

TABLE OF CONTENTS

REPORT OF THE BOARD	3
FINANCIAL STATEMENTS	
Balance Sheet as per 31 December 2024	
Profit and Loss Account 2024	
Generally accepted accounting principles for valuation and determination of results	
Notes to the Balance sheet as per 31 December 2024	
Notes to the Statement of income and expenditures 2024	10

REPORT OF THE BOARD

Stichting TB Europe Coalition (hereinafter – TBEC or the Foundation) is registered at the Dutch Chamber of Commerce in Amsterdam with registration number 858222565.

The members of the TBEC Board are pleased to present the Foundation's 2024 financial statement.

Vision, Mission and Core Values

TBEC vision: a world free of TB.

TBEC **mission**: civil society driving the TB response.

Core Values:

- Human Rights and Gender-Balanced Approach: Prioritizing dignity, autonomy, and rights of TB-affected individuals, ensuring equitable access to quality healthcare free from stigma and discrimination, with a focus on children and adolescents.
- **Social Justice**: Addressing social and economic determinants of TB, such as poverty, stigma, and discrimination, through people-centered care to tackle health inequalities.
- **Empowerment**: Enabling civil society and TB-affected communities to meaningfully participate in the TB response, promoting comprehensive and inclusive healthcare solutions.
- Accountability: Promoting multisectoral collaboration under National TB Programmes and WHO's Multisectoral Accountability Framework (MAF-TB) to ensure accountability across health sectors.
- **Independence and Transparency**: Accepting funding only from donors aligned with TBEC's vision, maintaining transparency in resource allocation, and challenging oppression caused by power inequalities.

Objectives:

- Building Capacity of Civil Society and Communities: Enhance civil society's capacity for TB prevention, diagnosis, and care, including knowledge of new TB technologies and cocreating people-centered services.
- Maintain TBEC Leadership in Communities, Rights and Gender (CRG) Advocacy:
 - Lead CRG advocacy efforts.
 - Expand the Standardized Package of Community-Based Support Services to five additional countries.
 - Advocate for access to new TB drugs and diagnostics via engagement with national TB Caucuses.
 - Promote social protection and Universal Health Coverage in Eastern Europe and Central Asia.

• TBEC's Institutional Development Through Research and Innovation:

- o Develop a social science research agenda to explore TB-related social issues and behavioral patterns.
- Support innovation in TB care and prevention through community-engaged research.

• TBEC Partnership and Strategic Geographical Expansion:

- Build partnerships with EU health organizations to influence TB policies in lowburden and EECA countries.
- o Transfer best practices to/from EECA by engaging patient organizations.

• Achieving Financial Stability:

- Seek project funding from diverse donors.
- Pursue unrestricted funding from private individuals, institutions, and crowdfunding platforms.

The Foundation makes every effort inter alia to attain and accomplish its objective by:

- being a regional civil society network bringing together both individuals and organisations from across the region in order to strengthen the role of civil society within the regional response to tuberculosis, health and well being, and to increase the political and financial commitment required to effectively manage both the tuberculosis epidemic, and increase the health and well-being of all persons; and
- o collaborating with medical, governmental, private, and civil society bodies of all types.

The Foundation does not have the objective to make profits.

Projects

In 2024, TBEC had 9 projects:

- 1) as grantee under the Stop TB Partnership/UNOPS "Challenge Facility for Civil Society" Round 10;
- 2) as grantee under the Stop TB Partnership/UNOPS "Challenge Facility for Civil Society" Round 12;
- 3) as grantee under the Stop TB Partnership/UNOPS "Support to the TB Procurement and Market-Shaping Action Team (TPMAT) in expanding partnerships and engaging and coordinating stakeholders";
- 4) as grantee under the Global Fund, Switzerland (CRG Project, 2024 2026), Long term capacity strengthening of TB community networks and organizations;
- 5) as a service provider for the GF TA Project "CCM Evolution Engagement CLM Training";
- 6) as a service provider for the GF TA Project "CCM Ukraine Composition review TA";
- 7) as a service provider for the GF TA Project "CCM Kyrgyzstan TA for CCM Member Elections and Meaningful Engagement";
- 8) as a service provider for the GF TA Project "CCM Kazakhstan: Engagement Support for CCM Member Elections/Selections"
- 9) as grantee under the TAG ASCENT DR-TB CATALYTIC small grants

Board Members

As of 31 December 2024, TBEC Board consisted of 13 members:

Mr. Paul John Sommerfeld	Chair
Ms. Yuliya Chorna	Co-Chair
Dr. Jonathan Joseph Stillo	Vice-Chair
Mr. Stefan Radut	Vice-Chair/Treasurer
Ms. Mona Drage	Board Member
Ms. Kira Grozava	Board Member
Ms. Cristina Enache	Board Member
Mr. Denis Godlevskiy	Board Member
Mr. Daniel Kashnitsky	Board Member
Ms. Cristina Celan	Board Member
Ms. Oleksandra Denysenko	Board Member
Ms. Oxana Rucşineanu	Board Member
Mr. Bakyt Myrzaliev	Board Member
	Mr. Paul John Sommerfeld Ms. Yuliya Chorna Dr. Jonathan Joseph Stillo Mr. Stefan Radut Ms. Mona Drage Ms. Kira Grozava Ms. Cristina Enache Mr. Denis Godlevskiy Mr. Daniel Kashnitsky Ms. Cristina Celan Ms. Oleksandra Denysenko Ms. Oxana Rucşineanu Mr. Bakyt Myrzaliev

The members of the Board do not receive any reward for their endeavour and contribution to the TB Europe Coalition.

FINANCIAL STATEMENTS

Balance Sheet as per 31 December 2024

(EUR)

ASSETS	Notes	31/12/2024	29/12/2023
Current assets		122.399,00	103.137,00
Receivables		0	0
Deferred income		0	0
Cash and cash equivalents	1	122.399,00	103.137,00
		122.399,00	103.137,00

LIABILITIES	Notes	31/12/2024	29/12/2023
Financing		122.399,00	103.137,00
Restricted Financing	2	61.063,00	103.137,00
Unrestricted Financing	3	61.336,00	0
Payables		0	0
Accrued expenses		0	0
		122.399,00	103.137,00
		122.399,00	103.137,00

TBEC, as a non-profit organisation, does not recognize commitments for future contracts or expenses until official confirmation of funding has been received from donors. Agreements for the provision of goods or services may only be signed after donor reports have been reviewed and subsequent tranches approved. This explains the absence of receivables and payables as of the balance sheet date.

projects activities

SURPLUS/(DEFICIT)

Profit and Loss Account 2024

(EUR)

779,275.00

(-288, 818.00)

INCOME	Notes	2024	2023
Income from own fundraising	9	368.274,00	490.457,00
Grants from International Foundations/NGOs	3	368.274,00	490.457,00
Grants from businesses			
Other: Donations			
Other income:		66.036,00	0.00
Unrestricted income	A	66.036,00	0.00
		434.310,00	490.457,00
EXPENDITURES	Notes	2024	2023
Implementation of the	В	437.124,00	779,275.00

Note A: Unrestricted income in 2024 includes funds received as reimbursement for expenses previously covered by TBEC from its own resources within the framework of a completed donor-funded project. These funds are no longer subject to donor restrictions and are therefore classified as unrestricted income, available to support the organisation's operational and strategic needs.

437.124,00

(-2.814,00)

Note B: Expenditures within the EU-funded project were partially covered by TBEC's unrestricted funds and were reimbursed by the EU upon final report approval in 2024. The reimbursement was recorded as unrestricted income.

Generally accepted accounting principles for valuation and determination of results

Accounting policies

The financial statements have been prepared in conformity with generally accepted accounting principles in the Netherlands. The statements are based on a reporting period of one year. The fiscal year coincides with the calendar year. The financial statements are presented in Euros, rounded to the nearest Euro. Transactions denoted in foreign currencies are converted using the Central European Bank's exchange rate on the date of the transaction. Monetary assets and liabilities denoted in foreign currencies are translated using the Central European Bank's exchange rate on the balance sheet date. All assets and liabilities are recorded at nominal value.

Notes to the Balance sheet as per 31 December 2024

1. Cash and cash equivalents:

Bank account	Balance sheet (EUR)	Bank account (Account currency)
ABN AMRO main account balance (part unrestricted overheads and EU Project)	59.869,00	EUR 59.869,00
ABN AMRO foreign account balance (Stop TB Project, GDF Project, TAG Project)	9.394,00	USD 9.759,00
ABN AMRO foreign account balance (CRG Project, GF TA Projects (incl. 1.467 EUR unrestricted overheads))	53.136,00	USD 55.203,00
TOTAL	122.399,00	

Balance in euros just rounded to the nearest Euro, balances in US dollars converted at the rate of the Central European Bank at the balance sheet date (31 December 2024).

TBEC does not use petty cash and does not have any deposits.

2. Restricted funding

Bank account		Balance sheet (EUR)	Bank account (Account currency)
TAG Project (Ascent DR-TB Catalytic small grants)		9.394,00	USD 9.759,00
The Global Fund, Switzerland (CRG Project, GF TA Projects)		51.669,00	USD 53.679,00
	TOTAL	61,063.00	

Balances at the balance sheet date (31 December 2024), the same conversion rule applies as in Note 1 above.

Notes to the Statement of income and expenditures 2024

3. Grants from International Foundations/NGOs

Source of funding	Profit and loss account (EUR)	Disbursement amount (Disbursement currency)
STOP TB Partnership/UNOPS STOP TB Project, Round 12		our enegy
2 nd disbursement	40,802.00	USD 45,000.00
Sub-total	40,802.00	USD 45,000.00
STOP TB Partnership/UNOPS STOP TB Project, Round 10		
5 th disbursement	21,887.00	USD 23,704.00
Sub-total	21,887.00	USD 23,704.00
STOP TB Partnership/UNOPS GDF Project 3 rd disbursement	75,620.00	USD 82,327.00
4 th disbursement	28,698.00	USD 31,686.00
5 th disbursement	12,349.00	USD 12,975.00
Sub-total	116,667.00	USD 126,988.00
The Global Fund, Switzerland (CRG Project, 2024 – 2026)		
1 st disbursement	138,324.00	USD 149,999.00
Sub-total	138,324.00	USD 149,999.00
The Global Fund, Switzerland, CCM Evolution Engagement CLM Training	,	,
2 nd disbursement	8,004.00	USD 8,756.00
The Global Fund, Switzerland, CCM Ukraine - Composition review TA	8,004.00	USD 8,756.00
1 st disbursement	2,644.00	USD 2,919.00
2 nd disbursement	6,489.00	USD 6,811.00
Sub-total	9,133.00	USD 9,730.00
The Global Fund, Switzerland, CCM Kyrgyzstan - TA for CCM Member Elections and Meaningful Engagement		
1 st disbursement	5,407.00	USD 5,853.00
2 nd disbursement	10,117.00	USD 11,285.00
Sub-total	15.524,00	USD 17.138,00
The Global Fund Switzerland, CCM Kazakhstan: Engagement – Support for CCM Member Elections/Selections		
1 st disbursement	8,692.00	USD 9,120.00
Sub-total TAG ASCENT DR-TB CATALYTIC small grants	8,692.00	USD 9,120.00
1 st disbursement	9.241,00	USD 10.000,00
Sub-total	9.241,00	USD 10.000,00
GRAND TOTAL	368,274.00	USD 400.435,00

Currency exchange policy. All foreign currency transactions are converted into euros using the official European Central Bank (ECB) exchange rate applicable on the transaction date.

Official ECB exchange rate printouts are retained for each relevant transaction and are available upon request. Year-end balances in USD are translated into euros using the ECB exchange rate as of 31 December 2024.

Expenditures on implementation of project activities includes:

- ✓ Consultancy fees: long- and short-term consultants;
- ✓ Program costs: events/travel/translation etc;
- ✓ Operational costs: administrative costs, google and zoom business annual subscription, legal costs, bank charges, exchange rates gains/losses etc.

4. Surplus/(Deficit)

Although the Statement of Income and Expenditures for 2024 reflects a deficit of €2.814,00 this does not indicate a cash shortage. The deficit results from the timing mismatch between the implementation of certain activities under the Global Fund Technical Assistance and Stop TB projects and the corresponding income recognition. Specifically, some funds were received in 2023 for activities implemented in 2024. The total cash balance as of 31 December 2024 remains positive (see Note 2 to the Balance Sheet).

Signed by the TBEC Board members (as	of June 2025):	Signed by:
Mr. Paul John Sommerfeld	Chair	Mr. Paul Josian Stanna Mild 52550DE4A64A496 Signed by:
Ms. Yuliya Chorna	Co-Chair	Ms. Uuliya (Elemature) D39064DDE08A40B Signed by:
Dr. Jonathan Joseph Stillo	Vice-Chair	(signature)
Mr. Stefan Radut	Vice-Chair/Treas	urer Stefan Kadsignature) 31FB5912DBB3492 Signed by:
Ms. Mona Drage	Board Member	(signature)
Ms. Kira Grozava	Board Member	(signature)
Ms. Cristina Enache	Board Member	(signature)
Mr. Denis Godlevskiy	Board Member	Signature) (signature)
Mr. Daniel Kashnitsky	Board Member	Signed by: (signature)
Ms. Cristina Celan	Board Member	OSE 34884EB63420 (signature) Rognucart: Ms. Olusandra Punysunko
Ms. Oleksandra Denysenko	Board Member	3648649F6F1649Е (Signature)
Ms. Oxana Rucşineanu	Board Member	Ms. Ozana kusini (signature) F544A6A2129A41D TOGRINGANT:
Mr. Bakyt Myrzaliev	Board Member	Mr. Bakyt Myrzali(signature)